Your browser is no longer supported. Please, upgrade your browser.
Settings
ADAP Adaptimmune Therapeutics plc daily Stock Chart
ADAP [NASD]
Adaptimmune Therapeutics plc
Index- P/E- EPS (ttm)-1.02 Insider Own0.22% Shs Outstand107.47M Perf Week-5.22%
Market Cap351.43M Forward P/E- EPS next Y-1.08 Insider Trans0.00% Shs Float11.25M Perf Month-5.49%
Income-102.20M PEG- EPS next Q-0.33 Inst Own73.20% Short Float32.51% Perf Quarter-20.63%
Sales51.30M P/S6.85 EPS this Y-23.00% Inst Trans-0.05% Short Ratio12.62 Perf Half Y-35.12%
Book/sh2.10 P/B1.56 EPS next Y5.30% ROA-38.30% Target Price7.42 Perf Year-70.54%
Cash/sh1.56 P/C2.09 EPS next 5Y1.00% ROE-45.00% 52W Range3.20 - 14.54 Perf YTD-43.13%
Dividend- P/FCF- EPS past 5Y-56.20% ROI-33.60% 52W High-77.51% Beta1.62
Dividend %- Quick Ratio8.50 Sales past 5Y178.50% Gross Margin- 52W Low2.19% ATR0.22
Employees430 Current Ratio8.50 Sales Q/Q- Oper. Margin- RSI (14)38.24 Volatility4.99% 6.23%
OptionableYes Debt/Eq0.00 EPS Q/Q-18.80% Profit Margin- Rel Volume0.63 Prev Close3.44
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume289.86K Price3.27
Recom2.10 SMA20-10.79% SMA50-11.32% SMA200-37.84% Volume183,338 Change-4.94%
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17Initiated Wells Fargo Market Perform
Oct-24-16Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16Initiated Raymond James Outperform $16
Feb-25-16Initiated Citigroup Buy $15
Jun-01-15Initiated Leerink Partners Outperform $24
Jun-01-15Initiated Guggenheim Buy
Jun-01-15Initiated BofA/Merrill Neutral
Jul-18-19 11:00AM  How Should Investors Feel About Adaptimmune Therapeutics plc's (NASDAQ:ADAP) CEO Pay? Simply Wall St.
08:00AM  Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGEA4 to Enhance Antitumor Responses GlobeNewswire
Jul-09-19 11:23AM  Athenex (ATNX) in Focus: Stock Moves 6.5% Higher Zacks
09:00AM  Adaptimmune Therapeutics PLC (ADAP) Upgraded to Strong Buy: Here's Why Zacks
Jun-29-19 05:37PM  Is Adaptimmune Therapeutics plc (ADAP) Going to Burn These Hedge Funds? Insider Monkey
Jun-27-19 02:54PM  Hedge Funds Piled Into This Stock Right Before Its 40% Ascend Insider Monkey
08:00AM  Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer GlobeNewswire
May-28-19 10:14AM  Those Who Purchased Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Have A 72% Loss To Show For It Simply Wall St.
May-15-19 12:28PM  AdaptImmune partners to advance promising cancer immunotherapies American City Business Journals
08:00AM  Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products GlobeNewswire
May-06-19 07:30AM  Adaptimmune Reports First Quarter 2019 Financial Results GlobeNewswire -5.82%
07:00AM  Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors GlobeNewswire
May-02-19 07:00AM  Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting GlobeNewswire
May-01-19 08:00AM  Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019 GlobeNewswire
Apr-18-19 04:01PM  Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting GlobeNewswire
Apr-12-19 03:26PM  These 3 Falling Knives Are Expected to Outperform GuruFocus.com
Apr-02-19 08:00AM  Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting GlobeNewswire +8.29%
Apr-01-19 08:00AM  Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-15-19 12:06PM  Does Adaptimmune Therapeutics plc (NASDAQ:ADAP) Have A Particularly Volatile Share Price? Simply Wall St.
Mar-06-19 12:15PM  Edited Transcript of ADAP earnings conference call or presentation 27-Feb-19 1:00pm GMT Thomson Reuters StreetEvents -8.66%
Feb-27-19 07:29AM  Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update GlobeNewswire
Feb-07-19 11:01AM  Should You Worry About Adaptimmune Therapeutics plcs (NASDAQ:ADAP) CEO Salary Level? Simply Wall St.
08:00AM  Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019 GlobeNewswire
Jan-28-19 09:38AM  Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know Zacks
Jan-08-19 04:30PM  Radius Exceeds 2018 Financial Guidance, Provides Updates Zacks
09:54AM  Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4 Zacks
Jan-07-19 07:30AM  Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews GlobeNewswire +5.94%
Jan-02-19 10:12AM  What Percentage Of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Do Insiders Own? Simply Wall St.
Dec-12-18 08:30AM  Adaptimmune Announces that Gwen Binder will leave in January 2019 GlobeNewswire -8.70%
Nov-28-18 08:30AM  Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-20-18 07:52AM  Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-14-18 11:10AM  What You Must Know About Adaptimmune Therapeutics plcs (NASDAQ:ADAP) Financial Strength Simply Wall St. -5.83%
Nov-06-18 07:30AM  Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update GlobeNewswire -8.42%
Oct-25-18 04:30PM  Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018 GlobeNewswire
08:53AM  3 Beaten-Down Biotech Stocks: Can They Bounce Back? Motley Fool
07:29AM  Adaptimmune Therapeutics Worldwide Enters Oversold Territory Zacks
Oct-22-18 09:48AM  Adaptimmune's stock tumbles after cancer study results prompts price target cut MarketWatch -29.83%
Oct-20-18 10:45AM  Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress GlobeNewswire
Oct-17-18 07:20AM  Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis Discovering Underlying Factors of Influence GlobeNewswire
Oct-08-18 06:10PM  Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress GlobeNewswire -5.04%
Sep-19-18 07:30AM  3 Biotech Stocks That Big Investors Are Snatching Up Barrons.com
Sep-13-18 09:19AM  Should You Be Holding Adaptimmune Therapeutics plc (NASDAQ:ADAP) Right Now? Simply Wall St.
Sep-07-18 01:14PM  Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares GlobeNewswire
Sep-05-18 07:30AM  Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares GlobeNewswire
Aug-24-18 10:37AM  Options Traders Expect Huge Moves in Adaptimmune (ADAP) Stock Zacks +11.05%
Aug-20-18 08:30AM  Investor Expectations to Drive Momentum within NEXEO SOLUTIONS, Altisource Portfolio Solutions S.A, Celestica, Star Bulk Carriers, Criteo S.A, and Adaptimmune Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Aug-15-18 07:30AM  Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort GlobeNewswire
05:34AM  Edited Transcript of ADAP earnings conference call or presentation 2-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-02-18 07:30AM  Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update GlobeNewswire
06:00AM  Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call ACCESSWIRE
Jul-26-18 01:18PM  Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018 GlobeNewswire
Jul-24-18 12:20PM  Why AdaptImmune collected $27.5M from GSK American City Business Journals
07:30AM  GSK and Adaptimmune Complete Transition of NY-ESO SPEAR T-cell Therapy Program to GSK GlobeNewswire
Jul-18-18 08:32AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:29AM  Adaptimmune Announces Favorable Review of Safety from One Billion Cell Dose Cohort in MAGE-A10 SPEAR T-cell Study and Initiation of Third Dosing Cohorts GlobeNewswire
Jun-27-18 10:52AM  Investors Are Undervaluing Adaptimmune Therapeutics plc (NASDAQ:ADAP) By 21.72% Simply Wall St.
Jun-11-18 07:30AM  Study published in Cancer Discovery Indicates that NY-ESO SPEAR T-cells are Long-lived, Selfrenewing, and Capable of Persistent Anti-Tumor Effects GlobeNewswire
Jun-07-18 07:45AM  Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks ACCESSWIRE
Jun-04-18 07:30AM  Adaptimmune Presents Detailed Safety Update from Ongoing MAGE-A10 Pilot Studies at ASCO GlobeNewswire
07:30AM  Adaptimmune Announces First Patient to Receive One Billion Target Cell Dose after Positive Safety Data from Pilot Study with MAGE-A4 SPEAR T-cells GlobeNewswire
Jun-02-18 08:00AM  Updated Myxoid/Round Cell Liposarcoma Data with NY-ESO, Presented at ASCO Annual Meeting, Further Supports Promising Benefit: Risk Profile GlobeNewswire
Jun-01-18 07:30AM  Investor Expectations to Drive Momentum within SK Telecom Co., Adaptimmune Therapeutics, Fiat Chrysler Automobiles N.V, Achillion Pharmaceuticals, Pzena Investment Management, and Sasol Discovering Underlying Factors of Influence GlobeNewswire
May-16-18 05:00PM  Myxoid/Round Cell Liposarcoma Data with NY-ESO and MAGE-A10 Study Update to be Presented at American Association for Clinical Oncology (ASCO) Annual Meeting GlobeNewswire
May-15-18 06:59PM  Cramer's lightning round: Take a pass on Bristol-Myers Sq... CNBC Videos
06:47PM  Cramer's lightning round: Take a pass on Bristol-Myers Squibb shares for now CNBC
May-14-18 01:27PM  Edited Transcript of ADAP earnings conference call or presentation 9-May-18 12:00pm GMT Thomson Reuters StreetEvents
07:20AM  Wired News VBI Vaccines Reports Positive Data from Final Phase-1 Study for Preventative CMV Vaccine ACCESSWIRE
May-10-18 09:44AM  Benzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results Benzinga
May-09-18 07:30AM  Adaptimmune Reports First Quarter 2018 Financial Results and Business Update GlobeNewswire +7.01%
Apr-25-18 08:00AM  Adaptimmune to Report First Quarter 2018 Financial Results and Business Update on Wednesday May 9, 2018 GlobeNewswire
Apr-16-18 02:00PM  Adaptimmune Presents MAGE-A4 and MAGE-A10 pre-clinical data at American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Apr-12-18 08:00AM  Adaptimmune Announces Changes to Board of Directors GlobeNewswire +7.78%
Apr-09-18 07:30AM  Report: Exploring Fundamental Drivers Behind Brookfield Property Partners, Grupo Financiero Galicia S.A, Adaptimmune Therapeutics, Radware, Mimecast, and Bandwidth New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Apr-06-18 08:00AM  Adaptimmune to Present Two Posters at the Upcoming American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-29-18 07:03AM  4 Strong Buy Biotech Stocks Poised to Explode TheStreet.com +7.26%
Mar-26-18 10:50AM  Adaptimmune Stock: How Long Will Rally Continue? Investopedia
Mar-21-18 11:19AM  GlaxoSmithKline prescribes commercial reboot for pharma division Reuters +10.04%
Mar-16-18 10:10AM  3 Hot Junior Biotech Plays Investopedia
Mar-15-18 09:30PM  Edited Transcript of ADAP earnings conference call or presentation 15-Mar-18 12:00pm GMT Thomson Reuters StreetEvents +18.78%
04:33PM  Why Noodles & Co., Blue Apron Holdings, and Adaptimmune Therapeutics Jumped Today Motley Fool
03:35PM  Here's What Lifted Adaptimmune Therapeutics plc Today Motley Fool
01:13PM  Adaptimmune Therapeutics shares soar 26% on news of positive early signs for cancer treatment MarketWatch
07:30AM  Adaptimmune Reports Fourth Quarter / Full Year 2017 Financial Results and Business Update GlobeNewswire
07:30AM  Adaptimmune Announces Responses in Second Solid Tumor Indication with NY-ESO SPEAR T-cells GlobeNewswire
06:00AM  Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call ACCESSWIRE
Mar-13-18 07:30AM  Investor Expectations to Drive Momentum within Methanex, YPF Sociedad Anonima, Adaptimmune Therapeutics, Horizon Pharma, Changyou, and China Yuchai International Discovering Underlying Factors of Influence GlobeNewswire
Mar-05-18 12:12PM  Adaptimmune to Report Fourth Quarter / Full Year 2017 Financial Results and Business Update on Thursday March 15, 2018 GlobeNewswire
Feb-12-18 03:26PM  Did Adaptimmune Therapeutics plcs (NASDAQ:ADAP) Recent Earnings Growth Beat The Trend? Simply Wall St.
Jan-08-18 08:00AM  Adaptimmune Announces Two Manufacturing Achievements on Its way to Become the First Fully Integrated TCR T-cell Therapy Company GlobeNewswire
08:00AM  Adaptimmune Announces Positive Safety Data from Pilot Studies with MAGE-A10 SPEAR T-cells and First Patient to Receive 1 billion Target Cell Dose GlobeNewswire
Jan-04-18 08:00AM  Paul Stead Joins Adaptimmune as Vice President of Business Development GlobeNewswire
Dec-05-17 05:00PM  Adaptimmune Data to be Presented at American Society of Hematology (ASH) Annual Meeting Confirm NY-ESO SPEAR T-cell Efficacy in Multiple Myeloma Pilot Study GlobeNewswire
Nov-14-17 07:40AM  Featured Company News - Adaptimmune Outlines Study Designs for Two T-Cell Clinical Trials - MAGE-A4 and NY-ESO SPEAR ACCESSWIRE
Nov-10-17 08:58AM  Adaptimmune Presents Study Designs for Ongoing MAGE-A4 and NY-ESO SPEAR T-cell Clinical Trials at the Society for Immunotherapy of Cancer (SITC) Annual Meeting GlobeNewswire
Nov-09-17 03:04PM  Valeant (VRX) Earnings and Revenues Beat in Q3, Stock Up Zacks
09:45AM  Merrimack (MACK) Q3 Loss Narrower than Expected, Stock Up Zacks
09:30AM  Catalyst (CPRX) Posts Narrower-Than-Expected Loss in Q3 Zacks
08:00AM  NY-ESO Data Presented at the Connective Tissue Oncology Society (CTOS) Annual Meeting Confirm Potential of Adaptimmunes SPEAR T-Cell Therapy GlobeNewswire
Nov-08-17 02:40PM  Adaptimmune Therapeutics Plc :ADAP-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017 Capital Cube
11:56AM  Agenus (AGEN) Reports In Line Loss in Q3, Revenues Lag Zacks
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Noble JamesChief Executive OfficerMay 16Option Exercise0.141,773,100253,5531,773,100May 17 06:00 PM
Bertrand William C JRChief Operating OfficerJan 14Sale5.372,27112,1943,731Jan 16 09:31 PM
Binder-Scholl Gwendolyn KnowltChief Technology OfficerJan 14Sale5.371,5148,1292,487Jan 16 09:31 PM
Rawcliffe AdrianChief Financial OfficerJan 14Sale5.373,08416,5593,318Jan 16 09:30 PM
Amado RafaelPresident, R & DJan 14Sale5.373,02816,2594,974Jan 16 09:31 PM
Alleva Lawrence MDirectorDec 17Buy0.8447,28039,71547,280Dec 19 08:04 PM
Binder-Scholl Gwendolyn KnowltChief Technology OfficerOct 01Sale13.7925,000344,7500Oct 02 07:58 PM
Viswanathan Ravi10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:49 PM
MOTT DAVID MDirectorSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:48 PM
SANDELL SCOTT D10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:49 PM
Sonsini Peter W.10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:49 PM
Florence Anthony A. Jr.10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:47 PM
KERINS PATRICK J10% OwnerSep 07Buy1.673,000,0005,000,10082,978,668Sep 10 04:48 PM
Behbahani AliDirectorSep 07Buy1.6712,000,00020,000,40012,000,000Sep 10 04:47 PM
BARRETT M JAMES10% OwnerSep 07Buy1.673,000,0005,000,10082,978,668Sep 10 04:45 PM
BARRIS PETER J10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:46 PM
BASKETT FOREST10% OwnerSep 07Buy1.6715,000,00025,000,50082,978,668Sep 10 04:46 PM
New Enterprise Associates 14, 10% OwnerSep 07Buy1.673,000,0005,000,10082,978,668Sep 10 04:45 PM
Binder-Scholl Gwendolyn KnowltChief Technology OfficerAug 29Sale10.2525,000256,2500Aug 31 08:02 PM